SG
INO icon

StoneX Group’s Inovio Pharmaceuticals INO Stock Holding History

StoneX Group’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.1K Buy
+14,252
New +$16.9K ﹤0.01% 1323

Other funds holding INO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
GAA
Green Alpha Advisors Niwot, Colorado $149M AUM 118.1% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.74B AUM 36.19% 1-Year Est. Return
PCIA
Prime Capital Investment Advisors Overland Park, Kansas $10.3B AUM 25.54% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
SI
Stephens Inc Little Rock, Arkansas $8.93B AUM 25.13% 1-Year Est. Return

StoneX Group's INO Position: Q2 2026 in Review

StoneX Group opened a new position in Inovio Pharmaceuticals (INO) in Q2 2026: 14,252 shares worth $18.1K. The stake represents ﹤0.01% of the portfolio and ranks #1323 among its holdings.

57 funds tracked by Wall St. Rank hold INO as of Q2 2026.

  • StoneX Group held 14,252 shares of Inovio Pharmaceuticals worth $18.1K as of Q2 2026.
  • Inovio Pharmaceuticals was a new StoneX Group position in Q2 2026.
  • Inovio Pharmaceuticals made up ﹤0.01% of StoneX Group's portfolio in Q2 2026, its #1323 holding.
  • 57 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on StoneX Group's 13F filing for Q2 2026, filed 12 Aug 2026.